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Abstract
Background: Mother-to-child transmission of HIV remains an important public health problem in sub-Saharan Africa. As
HIV testing and linkage to PMTCT occurs in antenatal care (ANC), major challenges for any PMTCT option in developing
countries, including Tanzania, are delays in the first ANC visit and a low overall number of visits. Community health
workers (CHWs) have been effective in various settings in increasing the uptake of clinical services and improving
treatment retention and adherence. At the beginning of this trial in January 2013, the World Health Organization
recommended either of two medication regimens, Option A or B, for prevention of mother-to-child transmission of HIV
(PMTCT). It is still largely unclear which option is more effective when implemented in a public healthcare system. This
study aims to determine the effectiveness, cost-effectiveness, acceptability, and feasibility of: (1) a community health
worker (CWH) intervention and (2) PMTCT Option B in improving ANC and PMTCT outcomes.
Methods/Design: This study is a cluster-randomized controlled health systems implementation trial with a two-by-two
factorial design. All 60 administrative wards in the Kinondoni and Ilala districts in Dar es Salaam were first randomly
allocated to either receiving the CHW intervention or not, and then to receiving either Option B or A. Under the standard
of care, facility-based health workers follow up on patients who have missed scheduled appointments for PMTCT, first
through a telephone call and then with a home visit. In the wards receiving the CHW intervention, the CHWs: (1) identify
pregnant women through home visits and refer them to antenatal care; (2) provide education to pregnant women on
antenatal care, PMTCT, birth, and postnatal care; (3) routinely follow up on all pregnant women to ascertain whether they
have attended ANC; and (4) follow up on women who have missed ANC or PMTCT appointments.
(Continued on next page)
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Background
Mother-to-child transmission of HIV
The Joint United Nations’ Programme on HIV/AIDS
(UNAIDS) estimates that 260,000 children globally were
newly infected with HIV in the year 2012 [1], the vast ma-
jority through vertical transmission of the virus from
mother to child. Thus, even though the number of HIV
infections in children decreased by an estimated 52% be-
tween 2001 and 2012, vertical transmission remains a sig-
nificant problem, particularly in sub-Saharan Africa (SSA)
[1]. Most of these infections are preventable. The World
Health Organization (WHO) estimates that in the absence
of any intervention the mother-to-child transmission
(MTCT) rate is 15 to 45% [2]. Several studies in low-and
middle-income countries have shown that by using mater-
nal triple antiretroviral (ARV) regimens it is possible to re-
duce the six-month MTCT rate to less than 5%, even in
low-resource settings (Table 1). The MTCT rate at six
m o n t h si so f t e nu s e da sa no u t c o m ei ns t u d i e so np r e v e n -
tion of MTCT (PMTCT). However, if breastfeeding
continues beyond six months of age, HIV can still be
transmitted.
The obstacles of late and low antenatal care uptake and
retention
WHO recommends the integration of PMTCT services
with maternal and child health services [10]. In inte-
grated PMTCT services, antenatal care (ANC) is the
key entry point for PMTCT services (for example,
through HIV testing). Therefore, in many low- and
middle-income countries, one of the major challenges
to achieving the maximum benefits from PMTCT ser-
vices is late and low ANC attendance. The first ANC
visit is often delayed and women attend a low overall
number of ANC visits [11,12]. WHO recommends that
pregnant women have their first ANC visit in the first
trimester of pregnancy and attend a total of at least
four visits [13]. In Tanzania, an estimated 98% of
women attended at least one ANC visit for their most
recent live birth [14]. However, only 43% made four
ANC visits or more, and only 15% of women attended
ANC during the first trimester of pregnancy
(Additional file 1). Late and inconsistent attendance of
ANC means that any pre-existing health problems
(such as sexually transmitted infections and anemia)
as well as problems arising during pregnancy (such as
urinary tract infections, malaria, gestational diabetes,
and pre-eclampsia) are more likely to be detected late,
thereby significantly increasing the risks of adverse
outcomes from these conditions to the health of the
mother and the newborn child [15]. Moreover, de-
pending on the delay in the first ANC visit, HIV-
infected women may not be initiated on ARVs at all or
may receive ARVs late in pregnancy, decreasing the ef-
fectiveness and efficacy of PMTCT [7].
Community health worker interventions to improve ANC
and PMTCT outcomes
This cluster randomized health systems implementa-
tion study, called the Familia Salama (Kiswahili for
‘safe family’) trial, will test the effectiveness, cost-
effectiveness, feasibility, and acceptability of a commu-
nity health worker (CHW) intervention in improving
ANC and PMTCT outcomes. While there is consider-
able evidence to show that CHW interventions can
contribute to child health improvements [16,17], the
evidence for the effect of CHW interventions on
reproductive health services (including ANC and
PMTCT) is scant [16,18]. A systematic review by
WHO on CHW interventions has found that for inter-
ventions with a maternal health component “almost all
of the CHW-driven interventional studies showed (…)
a[n] improvement in perinatal and postpartum service
utilization indicators” (WHO 2010) [16], but it noted
that few studies were conducted at large scale and none
had employed an experimental design. In addition, it
found a “remarkable dearth of information” on the
cost-effectiveness of CHW programs [16]. Concerning
PMTCT, the WHO review did not identify a single
study of a CHW intervention to increase PMTCT
uptake and/or retention [16]. Nonetheless, a more re-
cent systematic review by UNAIDS has identified
several examples of successful programs that use
CHWs to improve PMTCT uptake and retention. How-
ever, none of these programs were evaluated in a
randomized trial [19].
The Familia Salama trial will thus provide much
needed evidence on the effectiveness of community
health workers (CHWs) in increasing ANC and PMTCT
uptake and retention. The results of this study will be
particularly important as it is a large-scale randomized
health systems implementation trial, which also assesses
the acceptability, feasibility and cost-effectiveness of the
CHW intervention.
Sando et al. Trials 2014, 15:359 Page 2 of 13
http://www.trialsjournal.com/content/15/1/359WHO’s PMTCT Option A and Option B
HIV can be transmitted from mother to child during
pregnancy or childbirth through blood, or postnatally
through breast milk. Until the early 2000s, PMTCT trials
and WHO recommendations focused on preventing the
transmission of HIV during pregnancy, birth, and the
early postnatal transmission period. When WHO pub-
lished updated PMTCT guidelines in 2000, randomized
clinical trials had not tested PMTCT regimens with
ARVs beyond seven days postpartum for the mother and
six weeks postpartum for the infant [20]. Transmission
through breast milk after the first few weeks of life, how-
ever, remained a serious challenge. Given the over-
whelming benefits of breastfeeding, the lack of safe
alternatives to human milk in resource-limited countries,
and the documented risk of HIV transmission through
breastfeeding, there was an urgent need to make breast-
feeding by HIV-infected women safer by preventing
postnatal transmission of the virus [21,22].
In this context, research started to focus on how ARVs
can be given to the mother or the infant in the
postpartum period to reduce transmission rates while
allowing the infant unrestricted access to breast milk.
These studies showed promising results for prophylactic
ARVs administered to infants [9,22-26]. The scientific
evidence from these studies, along with new evidence on
safe feeding practices for HIV-exposed infants, early in-
fant diagnosis, and revised maternal ARV eligibility, led
to the updating of WHO’s PMTCT guidelines in 2010
[10].
In its 2010 guidelines, WHO recommended the imme-
diate initiation of lifelong triple ARV treatment for all
HIV-infected pregnant women with a CD4 cell count of
≤350 cells/mm
3, or who are in WHO clinical stage III
or IV of HIV disease irrespective of CD4 cell count
[10]. All infants born to pregnant women on lifelong
triple ARV treatment should receive nevirapine (NVP)
or zidovudine (AZT) for four to six weeks regardless of
feeding mode. This is in contrast to the 2006 guide-
lines, which recommended lifelong treatment for HIV-
infected pregnant women if the CD4 cell count was
<200 cell/mm
3, the woman was in clinical stage IV, or
Table 1 Studies conducted in low-and middle-income countries, which achieved a six-month mother-to-child HIV
transmission rate of ≤5%
Country Year Participants Maternal regimen Infant
regimen
Transmission rate at 6
months (95% confidence
interval)
Botswana [3] 2006-
2008
730 breastfeeding
women
1
Triple ARVs from 28-34 weeks until cessation of
breastfeeding
2
sd-NVP+
AZT for 4
weeks
1.1% (0.5%-2.2%)
Rwanda [4] 2005-
2007
Mothers of 227
breastfed and 305
formula-fed infants
Formula-feeding: triple ARVs from 28 weeks until
birth. Breastfeeding: triple ARVs until cessation of
breastfeeding
2
sd-NVP+
AZT for 7
days
Breastfed: 1.8%
3 (0.7%-4.8%)
Formula-fed: 1.0%
3
(0.3%–3.0%)
Mozambique [5] 2005-
2007
341 breastfeeding
mother-infant pairs
Triple ARVs from 15 weeks until cessation of
breastfeeding
2
sd-NVP+
AZT for 7
days
2.1%
Mozambique,
Malawi, and
Tanzania [6]
2004-
2006
809 formula-feeding
women
Triple ARVs from 25 weeks until cessation of
breastfeeding
2
sd-NVP+
AZT for 7
days
2.7%
Burkina Faso,
Kenya, South
Africa [7]
2005-
2008
Mothers of 805 infants
4,5 Group 1: triple ARVs from 28-36 weeks until cessa-
tion of breastfeeding
2,6
sd-NVP+
AZT for 7
days
Group 1: 4.9% (3.1%-7.6%)
Group 2: AZT during pregnancy +sd-NVP and AZT
at onset of labor
7,8
Group 2: 8.4% (6.0%-11.6%)
Kenya [8] 2003-
2009
Mothers of 487
breastfed infants
Triple ARVs from 34-36 weeks until cessation of
breastfeeding
2
sd-NVP 5.0% (3.4%-7.4%)
Tanzania [9] 2004-
2006
Mothers of 441
breastfed infants
Triple ARVs from 34 weeks until cessation of
breastfeeding
2
AZT+3TC
for 7 days
5.0% (3.2%-7.0%)
3TC, lamivudine; ARV, antiretroviral drugs; AZT, zidovudine; NVP, nevirapine; sd-NVP, single dose of nevirapine at birth.
1Of these 730 women, 560 had a CD4-count ≥200 cells/mm
3 and 170 a CD4-count <200 cells/mm
3 or an AIDS-defining illness.
2Women were advised to have concluded complete cessation of breastfeeding by 6 to 7 months postpartum, depending on the study.
3These are transmission rates at 9 months (not 6 months).
478% of infants born to women in each arm of the study were ever breastfed.
5This is the number of participants randomized at the beginning of the study.
6349 infants’ mothers were provided with this regimen.
7339 infants’ mothers were provided with this regimen.
8After a protocol amendment in 2006, women in the AZT arm also received AZT + 3TC 7 days postpartum.
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For pregnant women who are not eligible for lifelong
ARV treatment, the WHO 2010 guidelines recommend
either of two drug regimens for PMTCT. The recom-
mended maximum duration of breastfeeding, regardless
of the PMTCT option used, is 12 months unless a
nutritionally adequate and safe diet cannot be provided
without breast milk [10].
Option A: AZT prophylaxis from as early as 14 weeks
of gestation until delivery. If the woman has received AZT
for less than four weeks, then NVP (single dose)+AZT+
lamivudine (3TC) should be administered every 12 hours
during labor and delivery, and AZT+3TC for seven days
postpartum. If the woman has received AZT for more
than four weeks, another option is to continue AZT every
12 hours during labor and then stop ARV treatment.
Breastfeeding infants should be given NVP daily until one
week after stopping breastfeeding and non-breastfeeding
infants should be given NVP or NVP (single dose)+AZT
for four to six weeks after delivery.
Option B: one of the following triple ARV regimens
from as early as 14 weeks of gestation until one week
after stopping breastfeeding: (1) AZT +3TC+ lopinavir/
ritonavir (LPV/r), (2) AZT+ 3TC +abacavir, (3) AZT +
3TC +efavirenz (EFV), (4) tenofovir disoproxil fumarate
(TDF) +3TC (or emtricitabine) +EFV. All infants re-
gardless of feeding mode receive NVP or AZT for four
to six weeks.
Both the WHO 2010 and 2013 guidelines found that
the available evidence does not show whether one of the
two PMTCT options described above is more efficacious
than the other [10,28]. The WHO 2010 guidelines (the
most current guidelines available at the beginning of the
trial period) recommended that policymakers choose the
option more suited to their cultural context, health sys-
tem, and economic constraints [10]. However, it is still
unclear which option will be more effective, cost-
effective, feasible, and acceptable when implemented in
real-life public-sector health systems in SSA. For ex-
ample, regarding Option B, questions concerning poten-
tial adherence fatigue during the breastfeeding period
and harm to mothers and infants from prolonged expos-
ure to ARVs still remain largely unanswered [29]. It is
not known how such potential disadvantages compare to
the operational drawbacks of Option A, such as the need
for CD4 counts to determine the type of regimen to be
initiated, the needed changes from antepartum to intra-
partum and postpartum regimens, and the requirement
for extended NVP administration in breastfeeding infants
[29,30]. Evidence, particularly from large-scale, random-
ized health system trials, on these questions is needed for
policymakers to design locally appropriate and optimal
PMTCT policies.
WHO’s PMTCT Option B+
PMTCT has been a dynamic field in the past and recent
changes in WHO’s policy recommendations have been
rapid and not without controversy [29]. This trial was
designed when the latest policy guidance document on
PMTCT that WHO had published were the 2010
PMTCT guidelines. In 2013, WHO published a new
guideline on the use of ARV drugs for treating and pre-
venting HIV infection. In these updated guidelines Op-
tion A is no longer recommended [28]. In addition,
WHO added the so-called Option B+ as an alternative to
Option B. Under Option B+, all HIV-infected pregnant
women are started on ARVs irrespective of CD4 count
and as soon as they have been diagnosed as HIV-
infected.
Even though WHO no longer recommends Option A,
it is still widely used across SSA since the implementa-
tion of new PMTCT guidelines lag behind the WHO
recommendations in many countries, and this trial will
provide useful evidence for PMTCT programs in many
low- and middle-income countries. In its 2013 guide-
lines, WHO states that ‘research is needed to determine
how to optimize acceptability, adherence and retention
on antiretroviral therapy (ART) in pregnant and breast-
feeding women’ (p. 104) [28]. Improving acceptability
and retention in PMTCT care are central aims of the Fa-
milia Salama trial’s CHW intervention. In addition, the
trial will provide useful information for those sub-
Saharan African countries considering a transition from
Option A to Option B or Option B+. In this context, it
is important to note that in this trial and for practical
purposes Option B is very similar to Option B+, because
Option B and Option B+ do not differ during the course
of pregnancy and the breastfeeding period. It is only
once a woman has stopped breastfeeding that she would
either stop (under Option B) or continue her ART for
life (under Option B+). Since the entire length of this
study is only 17 months, most women participating in
this trial will have received the same treatment in the
Option B arms of the trial that they would have received
under the Option B+ policy. An important difference,
nevertheless, lies in the woman’s expectation regarding
the duration for which she should take ARVs, which
may have an influence on adherence and retention. By
working with, and collecting data from clinics and hospi-
tals in wards, which were required to change their
PMTCT regimen from Option A (the standard of care
in Tanzania) to Option B for this trial, we will gain im-
portant insights on the implementation challenges of
transitioning from Option A to Option B or B+ .
PMTCT in Tanzania
In 2010, the MTCT rate in Tanzania was 25% [31], with
77% of HIV-infected pregnant women [1] and 74% of
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(Additional file 1).
The government of Tanzania began offering PMTCT
services in 2000 [33]. These services have now been inte-
grated into Tanzania’s reproductive and child health ser-
vices and should, therefore, be provided by the clinical
staff in ANC, labor and delivery, and postnatal care facil-
ities. However, not all ANC facilities offer ARVs, in
which case women are referred to the ART treatment
program. In June 2012, Tanzania adopted WHO’s 2010
PMTCT guidelines and implemented Option A as the
standard of care. Apart from the treatment and prophy-
laxis of pregnant women and their newborns with ARVs,
Tanzania’s PMTCT program includes voluntary testing
of pregnant mothers with pre- and post-test counselling,
infant feeding counselling, and family planning. In
addition, the program includes the testing of HIV-
exposed infants using polymerase chain reaction (PCR)
at four to six weeks and six months after delivery, and a
rapid HIV-test after complete cessation of breastfeeding,
usually between 9 and 18 months after delivery [34].
Tanzania has decided to implement lifelong triple
ARVs for all HIV-infected pregnant women (Option B+)
in 2013 with a graduated rollout. Because of this deci-
sion the trial management team, in accordance with the
Data Safety and Monitoring Board and the Tanzanian
Ministry of Health and Social Welfare, decided to stop
the trial in May 2014 rather than in January 2015.
Objectives
The aim of this study is to determine the effectiveness,
cost-effectiveness, acceptability, and feasibility of the fol-
lowing two interventions when implemented in the
healthcare system in Dar es Salaam, Tanzania: (1) a
CHW intervention to increase ANC and PMTCT uptake
and retention, (2) WHO Option A versus B for PMTCT,
and (3) the interaction between the CHW intervention
and the two PMTCT options.
Methods/Design
Study duration
The trial is being carried out over a period of 17 months
from January 2013 to May 2014.
Study setting
The Familia Salama trial is being carried out in the
Kinondoni and Ilala districts, two of the three adminis-
trative districts of the Dar es Salaam region of Tanzania.
In 2012, 69% (2,995,660 out of 4,364,541) of Dar es
Salaam’s population lived in these two districts [35]. Dar
es Salaam is highly urbanized and is Tanzania’s most
densely populated region with 3,133 people per square
kilometer [35].
Similar to other regions in Tanzania, virtually all
women in Dar es Salaam attend at least one ANC visit.
However, the percentage of women who deliver at a
health facility (90%), have knowledge of MTCT (71% of
women knew that drugs can reduce the risk of MTCT)
and received HIV-counselling during ANC (85%) is
considerably higher in Dar es Salaam than in other
regions of Tanzania [14,36]. Dar es Salaam also has the
second highest HIV-prevalence (9% among women and
men aged between 15 and 49 years) of any region in
Tanzania [14].
Study design
The Familia Salama trial is a cluster-randomized con-
trolled trial that uses a two-by-two factorial design
(Figure 1). Together, the districts in which the trial
takes place have 60 wards. These wards were randomly
allocated to either the CHW intervention (36 wards)
or the normal standard of care in Dar es Salaam (24
wards). The two arms were then randomized again to
receiving either WHO Option A or Option B for
PMTCT (Figure 1). The number of clusters in the
arms varies to reflect the difference in the population
sizes in each ward.
The study is carried out by Management and Develop-
ment for Health (MDH, Tanzania). The Harvard School
of Public Health provides technical assistance for the
trial of the CHW intervention. MDH is a Tanzanian
organization based in Dar es Salaam, which works in
partnership with Tanzania’s Ministry of Health and So-
cial Welfare. It provides technical and financial support
to 50 HIV treatment sites, 17 tuberculosis clinics, and
180 PMTCT outlets across Dar es Salaam.
The community health worker intervention
The CHW intervention employs two cadres of health
workers that already exist in the public-sector health
system in Tanzania. The first cadre is CHWs. This
cadre is locally called home-based carers, or HBC, but
we will continue to refer to them as community health
workers, because the activities that these health
workers carry out are similar to those carried out by
CHWs in most other settings. The second cadre is
nurses who are responsible for community outreach
from clinical facilities and whose responsibility includes
following up with HIV-infected pregnant women in the
community when they miss a PMTCT appointment
(see below). This cadre is locally referred to as
community-based healthcare workers, or CBHC, but
we will refer to them as community outreach nurses in
this article, because this cadre is based in clinical
facilities rather than in the community.
In wards randomized to the CHW intervention, the
study received from the municipalities: (1) an additional
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ing cadre of 21 community outreach nurses, with one to
three nurses being assigned to each ward, and (2) a
cadre of 215 CHWs, who work in the neighborhood in
which their home is located. One to three CHWs were
assigned to each street in the intervention wards
depending on the size of the street.
Responsibilities of the community health workers
While the CHWs exist as a cadre in the public-sector
health system in Tanzania, they are currently not car-
rying out any specific activities to support ANC and
PMTCT uptake and retention in the districts where
the trial takes place. In the CHW intervention arms of the
trial they are employed to fulfill the following functions:
(1) identify pregnant women at the community level
through home visits and refer them to ANC; (2) routinely
revisit all identified pregnant women to check whether
they have taken up ANC and to support first and future
ANC uptake through information, education, and coun-
selling; (3) visit pregnant women at home who have
missed scheduled ANC or PMTCTappointments; (4) pro-
vide education to pregnant women and other household
members on maternal health, general health issues (such
as nutrition, immunization, and sanitation) and the im-
portance of delivering at a healthcare facility, testing for
HIV during ANC visits, PMTCT, breastfeeding, postnatal
care, seeking early and appropriate healthcare in case of
an illness during pregnancy. As is the standard in Dar es
Salaam’s healthcare system, the CHWs receive a monthly
stipend equivalent to $US35.
Following up with women who have missed an ANC or
PMTCT appointment
In control wards, only women who have missed a
PMTCT appointment are tracked, while in wards ran-
domized to the CHW intervention CHWs carry out
home visits to pregnant women who have missed either
a PMTCT or an ANC appointment. In addition, CHWs
in the intervention wards routinely revisit all pregnant
women to check whether they have attended ANC, until
the women have attended ANC for the first time.
In the community intervention control areas, the com-
munity outreach nurses contact women once they are
over seven days late for their ANC or PMTCT appoint-
ment to encourage them to attend. Contact is first
attempted by phone, and subsequently by a home visit.
In the wards receiving the CHW intervention, the
CHWs support the community outreach nurses in carry-
ing out home visits to pregnant women. During the first
ANC visit, the ANC nurse obtains the woman’s address
and a written description of where and how her home
can be found (a so-called map cue), as well as the
woman’s telephone number. The community outreach
nurses visit each ANC facility in their ward weekly to
collect the addresses and telephone numbers of all
women who are over seven days late for their ANC or
PMTCT appointment. The community outreach nurses
call these women to remind them of their appointment.
If a community outreach nurse cannot reach a woman
on the phone, s/he passes the information about the
woman on to a CHW who will subsequently try to visit
the woman. In addition, the community outreach nurses
collect forms for referral to ANC from the CHWs and
match them with the referral forms obtained from
women at the ANC facilities. The community outreach
nurses pass those referral forms for which there is no
corresponding clinic visit (signifying that the woman
was referred to ANC but did not attend) back to the
CHW for follow-up at the woman’s home.
Community sensitization activities
As part of the community health intervention, commu-
nity sensitization activities are organized in intervention
areas. The research team, along with project and munici-
pal community health coordinators, provide information
on maternal health and ANC to local leaders and en-
courages them to spread educational messages to their
60 wards
Community 
intervention
36 wards
WHO Option B
22 wards
(36,550 pregnancies)1
WHO Option A
14 wards
(35,622 pregnancies)1
Standard of 
care
24 wards
WHO Option B
14 wards
(37,098 pregnancies)1
WHO Option A
10 wards
(44,424 pregnancies)1
Figure 1 The randomization scheme of the Familia Salama trial.
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Development Committee at the ward level and the Mtaa
(Kiswahili for ‘neighborhood’) Executive Committee at
the neighborhood level.
The trial of WHO Option A versus Option B
WHO Option A is the current standard of care for
PMTCT in Tanzania [34]. In the wards allocated to Option
A, HIV-infected women who are not eligible for lifelong
ARV therapy receive AZT from 14 weeks of gestation (or
at the first PMTCT visit, if it takes place after the 14
th week
of pregnancy) until delivery. This is followed by 12-hourly
AZT+ 3TC during labor and delivery and for seven days
postpartum. If the woman has taken AZTfor less than four
weeks, an additional single dose of NVP is administered at
the onset of labor. HIV-exposed breastfeeding infants are
g i v e nN V Ps y r u po n c ead a yu n t i lo n ew e e ka f t e rs t o p p i n g
breastfeeding while non-breastfeeding infants are given
NVP syrup for six weeks after delivery. Tanzania’sP M T C T
guidelines recommend that HIV-infected women breast-
feed exclusively for the first six months and stop breast-
feeding 12 months after birth unless an adequate diet
cannot be provided to the infant without breast milk [34].
In the wards allocated to WHO Option B, HIV-
infected women not eligible for lifelong ARVs receive
AZT+ 3TC +EFV from the 14
th week of pregnancy until
one week after the complete cessation of breastfeeding.
Regardless of the feeding option, all HIV-exposed infants
in the Option B wards receive NVP syrup for four to six
weeks after delivery.
Both PMTCT options are provided by clinical staff in
ANC, labor and delivery, and postnatal care services.
Some ANC facilities, however, do not provide ARVs, in
which case the woman is referred to ART services.
HIV PCR testing for infants is the standard of care in
Tanzania [34]. In all wards, PCR is performed at four to
six weeks and six months after delivery and a HIV rapid
diagnostic test (RDT) is administered after the complete
cessation of breastfeeding, usually between 9 and 18
months of age. Infants’ CD4 count is measured every six
months as per the national guidelines. HIV-infected
pregnant women in all wards receive a daily double-dose
of trimethoprim/sulfamethoxazole (Co-trimoxazole™),
and exposed infants receive daily Co-trimoxazole™ syrup
until their mother has stopped breastfeeding and they
are confirmed to be HIV-uninfected.
Patient and health worker satisfaction
Patient satisfaction is a determinant of treatment uptake,
adherence and retention, as well as an important health
systems outcome in its own right [37,38]. Health worker
satisfaction, on the other hand, is an important determin-
ant of staff turnover [39], job-related motivation [40], and
health worker migration [41]. It is plausible that the type
of PMTCT option and the CHW intervention have effects
on patient and health worker satisfaction. Option B re-
quires more frequent visits to PMTCT facilities, which
may reduce patient satisfaction and increase health
workers’ workload and job dissatisfaction. At the same
time, Option B has been widely hypothesized to be sim-
pler to carry out than Option A, because it entails only
one treatment for all HIV-infected pregnant and breast-
feeding women [28]. This operational simplicity could
conceivably improve patient and provider satisfaction.
Similarly, the CHW intervention implies several changes
that could affect patient and provider satisfaction. The
home-based visits might lead to better or worse patient
evaluation of the performance of the public-sector ANC
and PMTCT systems. Leading and managing CHWs
might improve job satisfaction among the community
outreach nurses (since they now have greater spans of re-
sponsibility and have gained human resources to care for
pregnant women in the community), or it might reduce
job satisfaction (for example, if the community outreach
nurses feel inadequately prepared for managing large
numbers of CHWs).
In the Familia Salama study, we thus assess the causal
effects of Option B (versus A) and the CHW interven-
tion on patient and health worker satisfaction. To collect
these data, we administer a questionnaire to patients
and health workers in all four trial arms in the second
year of the implementation of the interventions.
Training
We have provided training in clinical PMTCT services
to the facility-based health workers participating in this
study to ensure that Option A and B are carried out as
assigned through the trial. In addition, we have trained
the CHWs and community outreach nurses in the deliv-
ery of the CHW intervention (Additional file 2). The
trainings were based on the Tanzanian National PMTCT
Training Curriculum and the Tanzanian Community-
Based Care Curriculum.
Study endpoints
The primary endpoints of this study are: (1) the percent-
age of pregnant women making at least four antenatal
clinic visits (as recommended by WHO); (2) the percent-
age of pregnant women delivering at a healthcare facility;
(3) the percentage of HIV-infected women receiving
PMTCT; (4) the percentage of HIV-exposed infants who
received a confirmatory HIV test by six weeks after the ces-
sation of breastfeeding; and (5) the percentage of infants
born to HIV-infected mothers who have acquired HIV by
6 weeks after the complete cessation of breastfeeding.
The secondary endpoints of this study are: (1) the per-
centage of pregnant women who were tested for HIV
during pregnancy or labor and delivery; (2) the number
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ANC for the first time; (3) the percentage of HIV-
infected pregnant women who completed PMTCT; and
(4) the percentage of HIV-exposed infants who received
PMTCT.
In addition to the designated primary and secondary
endpoints, we will assess the causal impact of the inter-
ventions on a range of other endpoints, which capture the
following outcomes: cost-effectiveness, social acceptability,
patient satisfaction, and health worker satisfaction.
Eligibility criteria
Inclusion criteria
All pregnant women who either attend ANC at any of
the clinics included in this study or who are identified
by the CHWs during the routine household visits as
eligible for participation in this study.
Exclusion criteria
Any pregnant woman who is not able to provide verbal
informed consent (for ANC attendees) or written
informed consent (for PMTCT attendees) is ineligible to
participate in the study.
Randomization procedure
The unit of randomization is a ward. A ward in the Ilala
and Kinondoni districts consists of two to ten streets and
6,742 to 106,946 inhabitants (mean: 49,928) [35]. The 60
wards in the Ilala and Kinondoni districts were divided
into five strata by type of facility (military, high level, or
standard level) and district (Ilala and Kinondoni). A ‘high
level’ facility was defined as having the capacity to manage
obstetric complications, including performing caesarian
sections, while a ‘standard level’ facility does not have this
capacity.
Based on prior empirical evidence, ANC and PMTCT
outcomes differ significantly by facility type and district.
Thus, the sample was stratified by these characteristics
to ensure adequate representation of the different
facilities in the final sample and to gain statistical effi-
ciency. Within each stratum, the wards were sorted in
descending order of expected number of pregnancies,
based upon the number of pregnancies reported in
August 2011. A block randomization was then applied.
The first four wards in each stratum were randomly
assigned to the four arms of the study. After each subse-
quent round of four assignments, the assignment prob-
abilities were revised to increase the probability that the
arms with lower numbers of pregnancies would be more
likely to be chosen, thereby achieving the best balance
across arms. This algorithm was repeated 500 times and
the run giving the greatest balance in the expected num-
ber of pregnancies across the arms was selected.
While pregnant women can change the ANC facility
they attend over the course of their pregnancy, clinicians
were advised to maintain women on the PMTCT option
on which they were started. Randomization into the
CHW intervention is based on the ward in which the
woman lives.
Sample size
We expect that approximately 150,000 pregnancies would
occur in the two districts during the study period, includ-
ing 10,500 pregnancies among HIV-infected women. This
figure is adjusted for the expected number of dropouts in
the current standard of care, as it was estimated using data
from the participating facilities’ ANC registration books
from 2011. We calculated the minimum detectable differ-
ence between the control and the intervention arms for
the primary endpoints, using methods for cluster-
randomized trials [42] with unequal cluster sizes [40], with
intra-cluster correlations between 0.001 and 0.030, as re-
ported from similar cluster-randomized studies in low-
and middle-income countries [43,44]. Primary outcome
rates were taken from Tanzanian national data and studies
conducted in Botswana [45] and Zimbabwe [46]. The
minimum effect sizes that can be detected with a Type I
error of 0.05 are modest and well within the range of what
could be expected from this study.
Data collection
The majority of the study data is collected from clinical
registers that are in routine use in the Tanzanian health-
care system (Additional file 3). However, we have intro-
duced five additional registers to record additional data
for the purposes of this study. Data from all of these reg-
isters is entered by specialized data entry personnel into
an electronic database written in Microsoft Access. A
data quality manager checks for data entry error and
data inconsistencies on an ongoing basis. In addition to
the assessment of endpoints for the final study analysis,
the data is further used to monitor study progress during
weekly review meetings throughout the study period.
The study team runs quality checks on all backups re-
ceived from the data entry personnel. These include the
percentage of missing values for the variables in the regis-
ter and standard error and plausibility checks. In addition,
the number of women entered in each clinical register is
compared to the monthly aggregate number reported by
the district level authorities. Any inconsistencies in the
data are discussed with individual data entry personnel
and, if necessary, followed up on with visits to the health-
care facility and a review of the clinical register in
question.
In addition, MDH has trained 30 nurses to mentor
nurses at two to five other healthcare facilities. Clinical
mentors visit their mentees’ facilities at least once a week.
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filling out of clinical registers and ensuring the availability
of HIV test kits and ARV drugs. The clinical mentorship
program has been implemented in all wards in this trial.
Economic evaluation
Based on our understanding of clinical activities,
PMTCT Options A and B/B+ require different types of
resources and different resource levels, but the real-life
cost-effectiveness of implementing these various options
in a setting like Dar-es-Salaam is not known. We will
empirically measure resource utilization in all four inter-
vention arms through a costing study. Health worker
time, by cadre, for an average patient-case throughout
the course of PMTCT will be estimated based on data
from an empirical time-motion study. Study field
workers with medical training will follow PMTCT
nurses, health officers, and doctors during randomly se-
lected clinic days to measure task times per PMTCT
patient visit. These times will be used to estimate
patient-case times, using the data available in the study
database on the number and types of clinic visits per pa-
tient over the course of PMTCT. Other resource
utilization, such as drugs and medical supplies, will be
estimated based on standard clinical guidelines comple-
mented by pharmaceutical and clinic records. Unit costs
will be collected based on administrative data from the
public-sector PMTCT program and procurement re-
cords, including health worker salaries, drug prices,
prices of diagnostic tests, and healthcare facility rents.
Data management
The study team trained a cadre of 20 data entry personnel
in data entry and management. These data entry
personnel work at the larger healthcare facilities in this
study where desktop computers have been installed for
data entry. When a clinical register is not in use, the data
entry personnel enter the data from the register into a
Microsoft Access database on the desktop computer.
There is a separate password-protected Microsoft Access
database for each register. In addition, some data entry
staff form a mobile team that visits smaller healthcare fa-
cilities and enters data from the registers into a database
on a laptop. To merge the data with the central database,
the same data personnel take a password-protected
backup of the clinic database on a laptop to the MDH
headquarters at regular intervals (daily to monthly,
depending on the size of the facility).
Analysis plan
The data will be analyzed by intention-to-treat analysis at
the participant level. Thus, participants will be assigned to
the cluster in which they were resident at the start of the
trial regardless of whether they move to other clusters or
out of the trial areas during the study period. We will,
however, still be able to determine the number of partici-
pants who crossed over between healthcare facilities or
are lost to follow-up by linking women across clinic visits
and clinical registers. To evaluate the effect of the inter-
ventions on the primary endpoints of this program, we
will fit robust clustered log-binomial models [47]. The
main primary endpoint of this trial is the percentage of in-
fants born to HIV-infected mothers who have acquired
HIV by 6 weeks after complete cessation of breastfeeding.
Thus, the primary analysis will be run for this endpoint;
other endpoints will be assessed in secondary analyses.
The robust score test will be used to assess the statistical
significance of intervention effects and the 95% confidence
intervals will be based on the robust variance. In this way,
the validity of inferences will not depend on the validity of
assumptions about the correlation structure within or be-
tween wards, or on assumptions of normality or homosce-
dasticity of generalized regression residuals.
On average, randomization eliminates confounding;
hence, the primary analysis will be unadjusted for poten-
tial confounding variables. However, because power can
often be improved by covariate adjustment, secondary
analyses will adjust for potential confounding for other
measured individual-level risk factors such as age, as
well as ward-level variables such as population size. To
assess the statistical significance of effect modification,
the likelihood ratio test will be used, comparing models
with main effects only to models that include relevant
cross-product terms. When significant effect modifica-
tion is detected, point and interval estimates of interven-
tion effects stratified by the effect modifier will be
presented. Because effect modifiers are not hypothesized
a priori, the study is not powered to detect effect modifi-
cation and we will cautiously interpret any post hoc ef-
fect modification observed. All analysis will be
conducted using the SAS statistical software package
(SAS Institute, Cary, North Carolina).
Interim analyses and stopping rules
The aggregate data (i.e., data not separated by assignment
to intervention or control arms) for each endpoint will be
analyzed continuously during this trial to monitor data
quality. In addition, an independent Data Safety and Mon-
itoring Board (DSMB) has been formed and meets bian-
nually to review data quality and completeness, progress
on the trial, adherence to the protocol, and the safety of
participants. The board includes two Tanzanian and two
United States-based scientists. In closed session, the study
team’s statistician provides the DSMB with data on each
endpoint disaggregated by assignment to intervention or
control arms. No other research team members have ac-
cess to this report.
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B is the PMTCT option recommended by WHO [28], and
because it is unlikely that the CHW intervention could
lead to adverse effects. However, safety endpoints are
reviewed alongside the primary and secondary endpoints
at each DSMB meeting. In addition, the DSMB was asked
to review the trial protocol as new PMTCT guidelines,
such as the WHO guidelines, are published. The DSMB,
therefore, reviewed the study protocol when the new
WHO 2013 guidelines were published and decided against
amending the study design or discontinuing the trial.
Ethical issues
Approvals
The National Institutes of Medical Research in Tanzania
granted ethical approval for the study in June 2012. The
institutional review board of the Harvard School of Pub-
lic Health approved the analysis of the trial of the CHW
intervention in January 2013; this study received con-
tinuing ethics approval in February 2014.
Consent
Verbal consent is obtained in the CHW intervention at
two time points: (1) by the CHWs before they enter a
household for a counselling and information session;
and (2) by the healthcare worker (a nurse or physician)
at the first ANC visit. In the trial of WHO Option A
versus Option B, the PMTCT health workers elicit
written informed consent from HIV-infected pregnant
women during their first PMTCT visit.
Confidentiality
Participants’confidentiality is protected several processes.
Firstly, for the information sessions provided during
home visits, the CHW and the pregnant woman will
j o i n t l yi d e n t i f yar o o mi nt h eh o u s eo rp l a c eo u t s i d et h e
house that allows for counselling in private. Secondly,
to reduce the risk of accidental disclosure of a woman’s
HIV status, the procedures in the CHW intervention
are the same for HIV-uninfected as for HIV-infected
pregnant women. Thirdly, database access is restricted
to a limited number of study staff for data entry and
extraction. In addition, all staff involved in the study
have been trained before initiation of the study to
ensure that they are aware of the rules regarding confi-
dentiality and data protection. All computers that are
used for data entry as part of this study are protected
by an individual password known only to the data entry
clerk. In addition, the study database on each computer,
where data from particular ANC and PMTCT clinics is
stored, is protected by an individual password. At
MDH, all computers and the study database are
protected by passwords. Only individuals who are
physically present at the MDH facility in Dar es Salaam
can access the central server database, i.e., it is not
possible to gain access from outside the facility. At any
point in time, only 5-7 specifically authorized data
entry staff at MDH have access to data in the central
server database. No other study researchers have access
to de-identified data in the central database.
Illness of participants
When CHWs detect illness in a family member during
their home-based visits, they will encourage referral to
an appropriate health facility to the best of their ability.
Sustainability and scalability
This trial will provide critical information on the scal-
ability and sustainability of WHO Option A versus B
and on a CHW intervention to improve ANC and
PMTCT uptake and retention. It achieves this by inte-
grating the interventions directly into the public-sector
healthcare system rather than building a parallel struc-
ture for the delivery of the trial interventions, and by
assessing feasibility, acceptability, and cost-effectiveness,
all of which are crucial to sustainability and scalability.
Dissemination of findings
The Tanzanian Ministry of Health and Social Welfare
(MHSW) has been involved in the planning of this study
from the start. In addition, three MHSW staff are mem-
bers of the study team. This collaboration will ensure
the dissemination of our findings to the MHSW on a
continuous basis through both informal (such as per-
sonal meetings) and formal channels (such as study
meetings and reports). In addition, the results of the
study will be disseminated to the respective participating
wards, antenatal clinics, and health workers through per-
sonal meetings and reports. Globally, the results of the
study will be published in academic journals and pre-
sented at relevant conferences.
Health systems implementation trial
This study can be categorized as a health systems imple-
mentation trial in contrast to other types of trials such
as clinical trials. The study is a health systems trial for
several reasons:
For one, the study is implemented through the public-
sector health system in two of the three districts of Dar
es Salaam. The trial has only become possible because
the Tanzanian MHSW and the National Institute of
Medical Research (NIMR) have supported it. The inter-
ventions themselves are implemented through the
public-sector health systems structures and processes in
Dar es Salaam, using only health worker cadres that
already exist in the Tanzanian public-sector health
system.
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ing health workers in all the facilities in the randomly se-
lected wards in the two study districts about this PMTCT
option. The trial team continues to engage on an ongoing
basis with the health workers providing PMTCTand ANC
in all four arms of the trial to ensure high fidelity in imple-
menting the different intervention exposures.
In addition, the outcomes are assessed using the real-
life public-sector health system’s data collection systems.
The trial team supports the routine data collection in-
cluding the extraction of a wide range of routinely col-
lected data into an electronic database and data quality
control. While a few additional variables are collected
specifically for this trial, most of the primary and
secondary outcomes of interest are collected through
the routine data collection mechanisms in place in the
Tanzanian public-sector health system, irrespective of
this study (see Additional file 3).
Finally, all pregnant women who seek ANC and
PMTCT services in the public-sector health system in
the Kinondoni and Ilala districts of Dar es Salaam are
offered to participate in the study. Unlike in clinical
trials, only a few selection criteria apply and the follow-
up of participants regarding exposure and outcomes is
carried out largely through the public-sector health
system and linkage of individuals across different
routinely collected data forms.
The study is an implementation trial because it assesses
(1) the effectiveness of PMTCT Option A and B and the
CHW intervention under the conditions of a real-life
health system in SSA that has performed imperfectly in
the past in ensuring universal PMTCT coverage of HIV-
infected pregnant women; (2) how the effects of PMTCT
Option B are modified by a CHW intervention; (3) out-
comes other than effectiveness that are essential to inform
health policy and practice, including cost-effectiveness,
technical feasibility, and the social acceptability of Option
B and the CHW intervention; and (4) the effects of Option
B and the CHW intervention on implementation
outcomes such as patient satisfaction, quality of care, and
health worker job satisfaction. In addition, the trial
attempts to affect PMTCT-related outcomes through a
CHW intervention that focuses on ensuring early and
comprehensive uptake of ANC (the initial health system
function that needs to perform well in order to detect
HIV-infected pregnant women and to link them success-
fully to PMTCT), and good retention in ANC and
PMTCT through home visits of pregnant women to
support continued ANC and PMTCT attendance
throughout the course of pregnancy.
Trial status
The study is funded by Comic Relief - UK and the Elton
John AIDS Foundation. The National Institute of
Medical Research in Tanzania approved the study in July
2012 and the institutional review board of the Harvard
School of Public Health approved the trial of the CHW
intervention in January 2013. Randomization, recruitment
of project staff, CHWs and additional community out-
reach nurses, and training of healthcare workers has been
completed. Enrollment in the trial commenced in January
2013. The trial will be stopped in May 2014. The trial is
registered at ClinicalTrials.gov under the registration
number EJF22802.
Additional files
Additional file 1: HIV/AIDS, ANC, birth attendance, and MTCT in
Tanzania.
Additional file 2: The facility- and community-based trainings in
the Familia Salama trial.
Additional file 3: List of data sources for the Familia Salama trial.
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